OVID
OVID
NASDAQ · Biotechnology

Ovid Therapeutics Inc

$2.40
-0.14 (-5.51%)
Financial Highlights (FY 2026)
Revenue
17.81M
Net Income
-42,742,890
Gross Margin
—
Profit Margin
-240.1%
Rev Growth
+69.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 35.9% 35.9%
Operating Margin -585.2% -526.7% -33.9% -31.3%
Profit Margin -240.1% -228.1% -26.8% -31.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 17.81M 10.53M 31.11M 33.06M
Gross Profit — — 11.16M 11.86M
Operating Income -104,203,760 -55,463,589 -10,543,713 -10,340,763
Net Income -42,742,890 -22,750,370 -8,350,078 -10,285,734
Gross Margin — — 35.9% 35.9%
Operating Margin -585.2% -526.7% -33.9% -31.3%
Profit Margin -240.1% -228.1% -26.8% -31.1%
Rev Growth +69.1% +69.1% +19.5% +23.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 32.20M 24.28M
Total Equity — — 114.62M 121.51M
D/E Ratio — — 0.28 0.20
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -103,491,360 -58,144,651 -13,566,183 -16,328,398
Free Cash Flow — — -8,976,737 -6,780,942